N
Google TrendGME (1000+) — GameStop Stock Hits a New 52-Week High: What's Going On?
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:gme1000+pope francis200+nicolò tresoldi500+michael olise1000+bank of america fine1000+club brugge500+rb leipzig200+saudi news1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Daratumumab, Lenalidomide" (30 stories)

Top Headline Story

How Do Long-Term MAIA and CEPHEUS Data Reinforce Daratumumab Use in NDMM?
Lead StoryCancerNetworktech
4d ago

How Do Long-Term MAIA and CEPHEUS Data Reinforce Daratumumab Use in NDMM?

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQcG9YNXFjLURnajVKeXRLYWxpR0VKSTNZUHVRMkV0UEpXMXpQMVJGWjdVUktMRUxvOE1adnQ5a1JLaFpXbUVvaThZSDBRS0tDck8yajNBUTJhMUNFVjB4VUxxanpfMXRNZDBDVTRGN21LcnFQZGxvNmJ3YW1oWldCRnF5ZVNIdjNTRHlrTVZpempaWDAwcU5STHhTUWVmbHJVTmhaNWhVQTlaSEh2?oc=5" target="_blank">How Do Long-Term MAIA and CEPHEUS Data Reinforce Daratumumab Use in NDMM?</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
1000+21m ago

gme

GameStop Stock Hits a New 52-Week High: What's Going On?

Filter stories
200+21m ago

pope francis

The Myth of St. Francis

Filter stories
500+31m ago

nicolò tresoldi

Nicolò Tresoldi, chi è l'attaccante del Bruges che spaventa l'Inter in Champions League

Filter stories
1000+31m ago

michael olise

The Ballon d’Or doesn’t capture football’s wonder – Michael Olise is proof | Zito Madu

Filter stories

Search Results for "Daratumumab, Lenalidomide"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis
Naturetech

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBHX3RMNzNqb20ycnAtVHNFUkpkNXFhQW5zeGVhN2t2SlM2UEdHbnRfTVJ5YnppTGFKUDdCYjVKUjlfVHZuQlNLSXpvRWlieEk0RDV3UGZaU0RwaEFNNFdj?oc=5" target="_blank">Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Treatment Selection After CD38 and Lenalidomide Refractoriness in Multiple Myeloma
Targeted Oncologypolitics

Treatment Selection After CD38 and Lenalidomide Refractoriness in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQc0NnVUxHOExLcjdGZGlJRXJCajYtc1hPYTE1c0pKRHhhNzN5RDAtcGFFLTFHLUN4ZS1fUDVfRHRVRDRzMzg1Q0xVMVR6OFloT0ZmQWZQdlBueTVORFR6RWpLSlNFMF84ZEpNOWJscmNCbmxVLUlQdDVXQ3N3WDhveEhodjR4ZnBrNE12OTZhdkg2TFFzZjliYmJvMWUwR195YXN4TlMzZFFYUHBDMnVvNWJNT1l3UQ?oc=5" target="_blank">Treatment Selection After CD38 and Lenalidomide Refractoriness in Multiple Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
OncLivegeneral

Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOaWpVMGg1Q0VUTXdZV2tHS0dGVXBaOEdyTjA1MU5XUkxacVc5TDBqSlk2UWZyWkpQVXdJMDRGTjVTNVRDM21vRVZYMkZWUGhSeUFmLWFhY0hKY3d2Rkd0RG8tUzlhdlczOFBCR3VWTW01QThUWU14TXlxbjBqdGc1WUhrUFZDZTEyWlhLWEpwYjVCSmpHdl9ONHJVNkxiSE1OTUF3Sm9RZEFycWNVSVh6R2s1bHJVam9lZFJnZ2dNVVdyMVBZYWhKXzZsT1FsVWpsdndv?oc=5" target="_blank">Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Six Years Later, Most Myeloma Patients on a Darzalex Regimen Are Still Progression-Free
Cure Todaygeneral

Six Years Later, Most Myeloma Patients on a Darzalex Regimen Are Still Progression-Free

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQMnB5NUpYSTh2YWlhNHZvaTd6bEd4R3ZTYWVsN0thdHN3cE5wMWJoVEluaWVvMDVqR0ZBZ2J1MXRrejA1dkM1bFVMYlhUdGhiWmsyUzZHZzJsRkFTTnRvLWMzamp3c05IVU95MGFnNE9paUYzcGNuX3JaTmRzNnh6eEVtTUFZZ0c4azYyT0VUbENXek9ZNVZhTUFzdVg1V0QxQkE0WXVIak1hbUVQVUF5SE81Y05WVmJD?oc=5" target="_blank">Six Years Later, Most Myeloma Patients on a Darzalex Regimen Are Still Progression-Free</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma
Pharmafilegeneral

NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQbmdjTG13V3VJOEo3b0NLandrWVJkS2hOUzU0SUVtbF9yMDVUQjdzRG8tZmdPa1FnOFh2ZXJiTGwyd1FHcC12S0FQRXRyeTI4bEN1OFFUMmRwNUVGRWVPeVdLeThCS1JDei1WMGs3SkZIVnVxNlNaeGRIRDYwZUNneENiMVNaSmJjbktSUWZmVTF4ejZucmttYkY4ajRfekZZeHhmVUtHYw?oc=5" target="_blank">NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma</a>  <font color="#6f6f6f">Pharmafile</font>

Read Full StoryMore like this
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
CancerNetworkgeneral

Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNSXIzal9yV1lOMVd3b1hOcXJNTUZETDlBYXNXdGVUV05FQkMtby02S0RvdjhCX0labUIydWhwTm1yd0padS15MWNpNEtBUzJncHVDOFUyUUJRN3E4YW9hRnFyX3RnNFowSHJMQTZOSllXWjdxMGpYLUgtandsRUJYLWFMeEtzNXR4dzRienFnNUlGVE94UURXYWNfUkhESldxTWZvSW05V1dFRUpSSERz?oc=5" target="_blank">Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma
Naturetech

MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9HMG9yWFhmN0t4cmhMSk1nUUV3V0hiRHJxckVqR0N0M0R5VGlfREkzR281UUlqMVFPcFpJNmhzQkVRZ2lBRDNDMzdYQnBiemEyWTBTUXcyblQwTmhZcl9R?oc=5" target="_blank">MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
How Subcutaneous Isatuximab Could Compete With Daratumumab in Multiple Myeloma
Pharmacy Timesgeneral

How Subcutaneous Isatuximab Could Compete With Daratumumab in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxOTFNkX3g0NDZ3LVZqcEtuSElrZzF0WnFxVTB0ellGVFJ2bHQ4Y09lODhmbzBnYlVHS0pqOUNQLUpiNjMzSDNGWTFIbUc1MnVXUG0ycUpwSmc2bTJodHVTYmhGUkFFMFczZU5hT2kzU3M4aGdHaW5jdXN4VWpsS1VPNGtUYkplazNJMERGTVg3YVJtRFNmSlJIR0xtZW5TZDN0UllqaWJuWHVBTDZZS0E2eWFYOA?oc=5" target="_blank">How Subcutaneous Isatuximab Could Compete With Daratumumab in Multiple Myeloma</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
NICE backs daratumumab quadruplet for transplant‑eligible myeloma
PharmaTimesgeneral

NICE backs daratumumab quadruplet for transplant‑eligible myeloma

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQNmpocEtmQUdFRmg1RzNSbWJlWHQ4WkNwY1QzSVlpRzlZVXBoTWdYWlRsbGY2RUNPdmNNRGxtbV9GMHlHVmg1NXlUUDVqVVZyQlQtTFJSNTRqVHZKdWtPT25LTy1HNUlwWGZWUElYRlo1emJOMTcxa2NfbTNUNkxtVHNmaVpXcS1QSEtBX2xDUGFVSEVxVjdhTGZHNA?oc=5" target="_blank">NICE backs daratumumab quadruplet for transplant‑eligible myeloma</a>  <font color="#6f6f6f">PharmaTimes</font>

Read Full StoryMore like this
Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS
Naturetech

Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1oWUxBaHZhLUxzWmF4Q2RZN2lqVXd1ZWdVMGw0bnRQbmtkNnhQd2x6OEFwTE43YThVNU5OWHplQlR2d1NyYXdjU09sZWllUDBDQ3lOWXN2NFFzSVZKSUFz?oc=5" target="_blank">Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Role of Dual Maintenance Remains Uncertain in Multiple Myeloma
Targeted Oncologytech

Role of Dual Maintenance Remains Uncertain in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOdUdxY2w1bEtXcVl5SWM5ZGVEQ3laOGt1enpLc2RPRDBHRFlwRTFzSFd6Q1VpeWQxaThMVkJQSjVzOVl3S2NGRmdsVlEydWJmcm1IWTkxU0FkWHRVTERGc1FpTXVvY0xMYXlJNnhSb0V2LUxLbUk4cktURVZQZklnMURmQVBnZmxHNzN2dm03TXZjNEJhajY0Rklwaw?oc=5" target="_blank">Role of Dual Maintenance Remains Uncertain in Multiple Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in Newly Diagnosed Myeloma
OncLivetech

Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in Newly Diagnosed Myeloma

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxPTGVoc2lwLWthY2l2S0x3SlFMa0xsTG8yZW9ycno3ZU9TdUJhYzFFdnowU3owb0JRNjQxVXlJSUZrU2MtcHoyZmpIZjY5dlAtWjBfQlpzcE1DM0dlZlB5MUV3TFVKci1yZy00QU5hS1lDWlJaOVR4RWFfSU8wWkpudlU4N0ROUTdScjFja0x6Y1lSRVpJUmxXb1VZNXNlT2xDdHdVSjV3RE0zSnZYcjBjM2hHVXUxRl9rTzQ4XzlCRFdXYjJLYzllTnZKc1RwekZwOWxrdmw3VHdWdUQ1NWd6MDdQQQ?oc=5" target="_blank">Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in Newly Diagnosed Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Approves Darzalex Faspro-VRd For Newly Diagnosed, Transplant Ineligible Multiple Myeloma
Cure Todaygeneral

FDA Approves Darzalex Faspro-VRd For Newly Diagnosed, Transplant Ineligible Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPZ2w0NEFlQUplamVaekRHVWNUX0tXWGxoSmNMMUZOZm9tTWpsTFZ5VjczN0I1YUF1WERpeGZTOFc5dmdqRVdNWXRTZXBVZGw5ejMzYXNfVEdkUUxrX2ozMVdZUTNEOEllb29TVlRucmlDWUxYSlJ4UTNMSldqNnZ5cGFzUWlMeUhEX3FuVHNWZThCQkUzdzA5RWFDYWNnaXFDS29TMXhQOFU1N3BxZWhZNTZoXy1BdHFVRG9fZVd0WQ?oc=5" target="_blank">FDA Approves Darzalex Faspro-VRd For Newly Diagnosed, Transplant Ineligible Multiple Myeloma</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
Belantamab Mafodotin Regimen Yields Enduring Responses in NDMM
CancerNetworkgeneral

Belantamab Mafodotin Regimen Yields Enduring Responses in NDMM

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNNm00eWprd21XY1pQNF92QWd6M3phLXMwOW5EUDlhOTJ5ODFPLWV6d3hTdFVHSThxby1YUnFjYUpnTk5iZlZnV2NDZEJoakFiVUNvX0dYLWU1OW80SVgyUF95RF9fMlkyT0g1YktRdHBsRDVNUXN5ano5d0xlU0hMMmJOeVphdmZkSFpqYXdKZWM0UUliUHQ4UU1lN3hFdw?oc=5" target="_blank">Belantamab Mafodotin Regimen Yields Enduring Responses in NDMM</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study
Naturegeneral

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5BRkJSd09lWl91alZYMDJUeE9vUmtVQl9tZmxzdnB5Y25NVWJTdTBNaXdSYV96OGFTbFNFZ3R1Y0NROTQ2T2JGSHVONTAwd25WVUZOTkFGUnE0bm9Tdy1N?oc=5" target="_blank">Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Daratumumab Combo Sets New OS Benchmark in Transplant-Ineligible NDMM
CancerNetworkgeneral

Daratumumab Combo Sets New OS Benchmark in Transplant-Ineligible NDMM

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNVXViTk9kNzQzcUdVbGhscHZad1BNWnB1N2pzakxSenVwaHhKNU9wLWZXOEpkUnNreGZlUkZZTXlrSmpWMEhheW5IN3NVa1Nva2lRdnNpWElPY3NHdklpR3IwRzk1SXRNSUx4dTA2MnNDV3BUMGJ5a3Fab2locUpiUGxNYzRfT0l6eVlrQmRzY1B3OWpIVjlyOW05T1ZycU1qcGhBZHpBTQ?oc=5" target="_blank">Daratumumab Combo Sets New OS Benchmark in Transplant-Ineligible NDMM</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial
Naturegeneral

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBDcE1DVlpKSHBIT05lNFI1aU10S1RjZTdMOHc3OEluZDdDSkF5ZFJQRjdNVUNmd1ZFUUZNMjFFMk51VUE0SlhhUEFKcVBUQlR1OUhad2xNcThjVTY5bjJZ?oc=5" target="_blank">Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Teclistamab Induction Shows Feasibility in Transplant-Eligible Myeloma
CancerNetworkgeneral

Teclistamab Induction Shows Feasibility in Transplant-Eligible Myeloma

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPeE9BbmpLSHhxdnVYeDVhV1BpWERMNHRpWDJfaERoYVRrT0x5c29VMVhLNmlidXNHU2JxdFVwZUlIbmp2cnVVUXIwamd5akpPQ0NhYUU4WXZwemJ0NmN5TU96YkFkekJaQllNejMxZm5nZTRZR1V5ekdNblYtbDZtRDFIVzFRVnFscWN5SHkxbXQzZm1VNmx6bTM3ck5SZ2U3UFVmbkQ1a2o?oc=5" target="_blank">Teclistamab Induction Shows Feasibility in Transplant-Eligible Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial
Naturegeneral

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5lanBDVjlRWXBLR1hLaVlldzRuNFpFOFMtN1dkU053cU5ueWNVSy1VZTZRM0F3dlB0ZllCM0k1WVFkZm8yaTRGYWFHZTZPS2ZiM1JIRXp5NVFtV3BCUWVv?oc=5" target="_blank">Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
FDA Approves Subcutaneous Daratumumab Combination in NDMM
CancerNetworkgeneral

FDA Approves Subcutaneous Daratumumab Combination in NDMM

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNTjkzZmlQNTU5VllZcTI0WHdFX01GZ3RySUhzRmZVdmlaRUQxZjEweDBlU0FGT2g4TFFuMXozU3Q0T1ctU255d2g0NGk3UmhybzhwWEFjd2hvZ0JSSUxNMGd0MDNVVTktRXJIeGt2ZUtxRDc1ZFFNSzkwX0VJMGJwUWRNQlBpelZvWGNsenRhYzZfR1VGQ3Y0?oc=5" target="_blank">FDA Approves Subcutaneous Daratumumab Combination in NDMM</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
CEPHEUS Final Analysis: DVRd Sustains Efficacy Benefits in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma
OncLivetech

CEPHEUS Final Analysis: DVRd Sustains Efficacy Benefits in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPX21zRldISHptSi13RVB5QWQ2V2VOMmFEY1hZQzFIXzhwNk5HTXhFWi1uT2tHSHZSR2pTOHlRTXFJa3FJdlpGZmVwal9Qa1pRSmhEcGFmZVA1c2c3dFZ4Z0U2blFhdjZTQ1FyRGZtZnR3elZvaTRzSGdpdHFONTNJMC0xOVBVODZVUXNIdzdoaXVXSTlWRDdxY2U0d18xYjQtU2d3NElXaXkta291U3VNUmFCNDBzRmpzcFROVDNGQlZfQVZpbEUzWUpRT0lvTWJhSkNpemppQzA?oc=5" target="_blank">CEPHEUS Final Analysis: DVRd Sustains Efficacy Benefits in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
OncLivegeneral

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNa2tla081cWthS3RWS2VuSERlLURBSjB0dzFHT0lrMnZHS09vNEtmUWZpRFlwMGw4VEs2d0dPQkVqOTFVTDdyWHo4NDBJZmxRQTR0emxzNW1zMjVDbmNmd1V2RG1ZYmFpUWdlak1MQm1SOHBvZDhuUXJjVWkzYXJoU2JlcUs5QjZIbTVpdkRLSDQyVjYxN3d0RTB0U2JVNk1WTkswbXVpcVE2M01pa0RocVZuOExfcFdw?oc=5" target="_blank">FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Daratumumab-VRd for Newly Diagnosed Multiple Myeloma: Oncology NPs Review Frontline CD38 Therapy and AE Management
Oncology Nursing Newsgeneral

Daratumumab-VRd for Newly Diagnosed Multiple Myeloma: Oncology NPs Review Frontline CD38 Therapy and AE Management

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxNQlp2LTU5LTJfRzJYejB1TWpaTkJYWWdscl9kVmo5d25kMmlMN3R3U0M0RmxGRlJ2aXFYbkVoM29YY0dRWVRRUzBuZHlmZE0tcHA5cFdiUXU4NnIzU0Jja3oyWWp1VThiamtLTFJXN0JTVzNCUnMzNGJnMlVsNjhNYXR2cUxRVnhJa1N0VTdhV0VucDNEQmtHbjQwSzM3X2lYZWNsaVdlT1NNQlhzQXpaQlZnNWRDRFUxVnhCZkllT0txQWhfQzJXRk1seXRvYzJWaHBkdkJfQUdGR2FaUVZPSVMwSQ?oc=5" target="_blank">Daratumumab-VRd for Newly Diagnosed Multiple Myeloma: Oncology NPs Review Frontline CD38 Therapy and AE Management</a>  <font color="#6f6f6f">Oncology Nursing News</font>

Read Full StoryMore like this
FDA Approves Daratumumab Quadruplet for Transplant-Ineligible Myeloma
Targeted Oncologygeneral

FDA Approves Daratumumab Quadruplet for Transplant-Ineligible Myeloma

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPZVBlS052cXdHN0s0c0ZLbk9CejJfdzhxS09lY240czZWQUYtMU5xV0dRc0JKQzVuaVFyZy1TcmVGWE1jRVdielFubGYwX3JlZ1JKa1NDRXVwTXZHQXQ2bDBuSGtucGJTWGtzT3ZxQ25KMWJ6WVFBMGpIN085N3VOSlRGZ19rLTdwYmZSdzh2bEFHbnE0WXNidnJyMVhFZXhibnpsZw?oc=5" target="_blank">FDA Approves Daratumumab Quadruplet for Transplant-Ineligible Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
FDA Approves Teclistamab Plus Subcutaneous Daratumumab for Relapsed/Refractory Multiple Myeloma
OncLivegeneral

FDA Approves Teclistamab Plus Subcutaneous Daratumumab for Relapsed/Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOUWpjbFc4TzFkRFFRb3hubXgzT2FaZnIxOTNETk9Lbk11TDBia1U0VFQ3azhXb2duLUEzMFVON2NjNkplZEdnRC1wNGlZM21ZMVByZ0FrTENNcVJrRFAzazI2RjloV2k1bDNUTUtDSWY1b1pHMnRPWkZseFpHVTh6ckoyNldqdUYyLWw4LXQ3VVZsSUZPeGF2UWVvTlhaanA2Nk5fZDJNTFZqQlZvb1dhUVJZS3lLVm5hWmw3eHozTk93dw?oc=5" target="_blank">FDA Approves Teclistamab Plus Subcutaneous Daratumumab for Relapsed/Refractory Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma
CancerNetworkgeneral

New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxObXR4MDNKU3EydEJSeldwbHNFS2I0M3IwUHREZHUzZHJCU2d2Z0VpX0MtMzh2V25MZGR1N1JaUGxUU0ZGaDNhd0g4c1F5d2xlS0hNZ2ZTbTRVRFFPQnhvSHUyQVExeEphNUdMSm5nX1VRSnNXTlZONnNyVzRBREx5bVhUQUtnMHRMT0VwTVduOVJNU1pSUE8yQlBhWERTY09QUnZHUjhfUDJGLVhP?oc=5" target="_blank">New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma
CancerNetworkgeneral

Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQdXdROUdnRjNGcmJNc25hMW50blNDRW05TU5xOXhLMVR2SUJvaEpHNjBPMnpUbklBVGROTTNXU1VpcC02aGJ0WUhqc1laZjVpSG9ZUWJibG1uY2FKUTI2WElIak1VVW5tSF84RjI4UDk1STBPd1VtRTNlekpFSnVLT3lLMTRURUU1NWFrQzlZalEzMG52QUZMdlJCZ3htb2RwN3R3NGJ5emRZSGhwMzVHamVWNUVTUQ?oc=5" target="_blank">Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Beyond SC Daratumumab: Emerging Therapeutic Approaches for Smoldering Myeloma
Targeted Oncologygeneral

Beyond SC Daratumumab: Emerging Therapeutic Approaches for Smoldering Myeloma

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNQjFTa3NiQXFiV1Y4Rkh5SEIyeVhObWc0MnRBXzAtZEx2c0MwT1BYUGJzSlQzdFY0SGwta0xmcEoyempabzgxUDByaW1LVUp6bG5EQkRRUFhyM2ppWUhuM0t4THZnakIxZEtsX0lGcDFfVGZtcHh0YzJsRS04VFBNRXo3Tkxzd3pnQk14ZmV4NnZWX0pEMWxrVm9hQXo4cDdreFVoZDdtOWZKbnp4cUE?oc=5" target="_blank">Beyond SC Daratumumab: Emerging Therapeutic Approaches for Smoldering Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
OncLivegeneral

SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNeFczZ2dyWnJZdWZrbU5qb0JwVVZKT1B3NFJvaVBFanF5N3lhWkFQdFBzVWkybE5kXzN2bXVaTnVxVWFzaEFoZTNaVk1USjZOVDlHcVJud1lLYVhMMHBNeUI1Rmg4RlkyNTM4aFpjRjVrRGZydVY5dHVNa0Jwek5RUzB0TDdkZFVMeE5pX0ZMM1RFVzJMUVRaQlVPSVhRWVg5eUJqbkhseW1zeDQySndnZFhVaHdtc0VY?oc=5" target="_blank">SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
"Daratumumab, Lenalidomide" — Live Google News Trends & Headlines